Innospec (NASDAQ:IOSP) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPS

Innospec (NASDAQ:IOSP - Get Free Report) released its earnings results on Tuesday. The specialty chemicals company reported $1.50 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.24, Zacks reports. Innospec had a positive return on equity of 10.28% and a negative net margin of 0.07%.Innospec Price PerformanceShares of Innospec stock traded down $0.44 during trading hours on Tuesday, reaching $86.14. The company had a trading volume of 268,968 shares, compared to its average volume of 162,617. The firm has a market cap of $2.13 billion, a PE ratio of -2,871.33 and a beta of 0.91. Innospec has a one year low of $70.10 and a one year high of $110.29. The business has a fifty day simple moving average of $80.66 and a 200 day simple moving average of $79.17. Institutional Trading of InnospecA number of hedge funds and other institutional investors have recently bought and sold shares of IOSP. Baird Financial Group Inc. lifted its stake in Innospec by 11.5% in the 1st quarter. Baird Financial Group Inc. now owns 2,170 shares of the specialty chemicals company's stock worth $206,000 after purchasing an additional 223 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Innospec by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,833 shares of the specialty chemicals company's stock worth $1,405,000 after buying an additional 645 shares in the last quarter. Millennium Management LLC boosted its stake in Innospec by 8,176.5% during the first quarter. Millennium Management LLC now owns 170,414 shares of the specialty chemicals company's stock valued at $16,147,000 after buying an additional 168,355 shares during the period. NewEdge Advisors LLC grew its position in Innospec by 37.4% during the first quarter. NewEdge Advisors LLC now owns 4,567 shares of the specialty chemicals company's stock worth $433,000 after buying an additional 1,243 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Innospec by 6.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 132,399 shares of the specialty chemicals company's stock worth $12,545,000 after acquiring an additional 8,014 shares during the last quarter. Institutional investors own 96.64% of the company's stock. Analyst Ratings ChangesIOSP has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Innospec from a "strong sell" rating to a "hold" rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Innospec in a research note on Monday, December 22nd. Finally, Wall Street Zen raised Innospec from a "hold" rating to a "buy" rating in a research report on Saturday, December 13th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Reduce".View Our Latest Stock Report on IOSPAbout Innospec (Get Free Report)Innospec Incorporated NASDAQ: IOSP is a global specialty chemicals company headquartered in Cleveland, Ohio. The company operates through three principal business segments: Fuel Specialties, Oilfield Services, and Performance Chemicals. In the Fuel Specialties segment, Innospec develops and supplies additives designed to enhance octane levels, improve combustion efficiency, reduce emissions and prevent deposit formation in gasoline and diesel engines. Its Oilfield Services division provides chemical technologies—such as surfactants, corrosion inhibitors and demulsifiers—to support exploration, drilling, production optimization and enhanced oil recovery operations.See AlsoFive stocks we like better than InnospecYour Bank Account Is No Longer SafeNvidia CEO Issues Bold Tesla CallBuy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseThis $15 Stock Could Go Down as the #1 Stock of 2026This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Innospec Right Now?Before you consider Innospec, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innospec wasn't on the list.While Innospec currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here